专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3838916B1 VACCINE USED FOR PREVENTING TOXOPLASMA GONDII INFECTION AND PREPARATION METHOD THEREFOR 有权转让
公开(公告)号：EP3838916B1
公开(公告)日：2023-12-06
申请号：EP18923744.9
申请日：2018-10-22
发明人： CAO, Lili , GONG, Pengtao , LI, Siming , CHEN, Xingyuan , DING, He , WANG, Dian , HOU, Feng
IPC分类号： A61K39/002 , C07K14/45 , C12N15/30 , C12N15/70 , C12N1/21 , A61P33/02

2. 发明公开

EP4163303A1 SYNTHETIC MULTI-EPITOPE CHIMERA AS A VACCINE AND TREATMENT FOR LEISHMANIASIS IN MAMMALS 审中-实审
公开(公告)号：EP4163303A1
公开(公告)日：2023-04-12
申请号：EP21822305.5
申请日：2021-05-26
申请人： Universidad Complutense De Madrid
发明人： MARTÍNEZ RODRIGO, Abel , MAS ZUBIRI, Alicia , CARRIÓN HERRERO, Francisco, Javier , ORDEN GUTIÉRREZ, José, Antonio , DE LA FUENTE LÓPEZ, Ricardo , DOMÍNGUEZ BERNAL, Gustavo
IPC分类号： C07K19/00 , C12N15/30 , A61K39/008 , A61P37/02
摘要： Synthetic chimera which includes four multi-epitope peptides against Leishmania. Each of the peptides has been selected from a Leishmania infantum protein. These are nucleosomal histones H2A, H2B, H3 and H4. The invention also relates to a pharmaceutical composition which includes the synthetic chimera. It also concerns a prophylactic and/or therapeutic vaccine against Leishmania spp. for use in mammals and especially in humans and dogs.

3. 发明公开

EP3615005A1 COMPOSITIONS AND METHODS FOR VACCINE DELIVERY 审中-实审转让
公开(公告)号：EP3615005A1
公开(公告)日：2020-03-04
申请号：EP18791678.8
申请日：2018-04-27
申请人： The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
发明人： DUTTA, Sheetij , BECK, Zoltan , ALVING, Carl , MATYAS, Gary
IPC分类号： A61K9/127 , A61K39/015 , C07K14/445 , C12N15/30 , A61K39/39

5. 发明授权

EP2258850B1 RECOMINANT VIRAL-BASED MALARIA VACCINS 失效
标题翻译：重组病毒为主疟疾疫苗
公开(公告)号：EP2258850B1
公开(公告)日：2013-07-17
申请号：EP10180000.1
申请日：2003-12-16
申请人： Crucell Holland B.V.
发明人： Pau, Maria Grazia , Holterman, Lennart , Kaspers, Jorn , Stegmann, Antonius Johannes Hendrikus
IPC分类号： C12N15/30 , C12N15/861 , A61K39/015 , C07K14/445 , A01N65/00
CPC分类号： C12N15/86 , A61K39/015 , A61K2039/5256 , C07K14/445 , C12N7/00 , C12N2710/10343 , Y02A50/412
摘要： The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alphaviruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be applied for immunization against different Plasmodium infections, such as infections by P.falciparum or P.yoelii. Novel codon-optimized circumsporozoite (CS) genes are disclosed. Preferably, replication-defective adenoviruses are used, derived of serotypes that encounter low titers of neutralizing antibodies. The invention therefore also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups, or in prime-boost set-ups in which compositions based on different serotypes can be applied.

6. 发明授权

EP1346049B1 EFFICIENT EXPRESSION OF PLASMODIUM APICAL MEMBRANE ANTIGEN 1 IN YEAST CELLS 有权
标题翻译：疟原虫顶端膜抗原1的在酵母细胞中有效表达
公开(公告)号：EP1346049B1
公开(公告)日：2012-08-01
申请号：EP01995077.3
申请日：2001-12-21
申请人： Stichting Biomedical Primate Research Centre
发明人： KOCKEN, Clemens, Hendricus, Martinus , THOMAS, Alan, William , BLACKMAN, Michael John , WITHERS-MARTINEZ, Chrislaine , HOLDER, Anthony Arthur
IPC分类号： C12N15/30 , C12N15/81 , C12N5/10 , C07K14/445 , A61K39/015 , G01N33/68
CPC分类号： C12N15/815 , A61K39/00 , C07K14/445 , Y02A50/412
摘要： A method of efficiently expressing Plasmodium AMA-1 ectodomain or a functional part, derivative, and/or analogue thereof, in a eukaryotic expression system. Preferably, the Plasmodium AMA-1 ectodomain is Pf AMA-1 ectodomain. This protein may be expressed in yeast, such as Pichia pastoris. Efficient expression is possible using a method for producing mRNA encoding the Plasmodium AMA-1 ectodomain in a yeast cell, comprising providing the yeast cell with a nucleic acid encoding Plasmodium AMA-1 ectodomain, the nucleic acid being modified to utilize the yeast cell's codon usage. Preferably, at least one putative yeast polyadenylation consensus sequence in the nucleic acid has been modified. More preferably, also at least one site in the protein that is generally glycosylated by eukaryotic expression systems, has been removed.

7. 发明授权

EP1573012B1 RECOMBINANT VIRAL-BASED MALARIA VACCINES 失效
标题翻译：重组病毒为主疟疾疫苗
公开(公告)号：EP1573012B1
公开(公告)日：2011-11-30
申请号：EP03796103.4
申请日：2003-12-16
申请人： Crucell Holland B.V.
发明人： PAU, Maria Grazia , HOLTERMAN, Lennart , KASPERS, Jorn , STEGMANN, Antonius, Johannes, Hendrikus
IPC分类号： C12N15/30 , C12N15/861 , A61K39/015 , C07K14/445
CPC分类号： C12N15/86 , A61K39/015 , A61K2039/5256 , C07K14/445 , C12N7/00 , C12N2710/10343 , Y02A50/412
摘要： The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alphaviruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be applied for immunization against different Plasmodium infections, such as infections by P.falciparum or P.yoelii. Novel codon-optimized circumsporozoite (CS) genes are disclosed. Preferably, replication-defective adenoviruses are used, derived of serotypes that encounter low titers of neutralizing antibodies. The invention therefore also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups, or in prime-boost set-ups in which compositions based on different serotypes can be applied.

8. 发明授权

EP1554383B1 REKOMBINANTE MVA-STAMME ALS POTENTIELLE IMPFSTOFFE GEGEN P. FALCIPARUM -MALARIA 有权转让
标题翻译：对恶性疟原虫-MALARIA重组MVA部族潜在的疫苗
公开(公告)号：EP1554383B1
公开(公告)日：2010-01-20
申请号：EP03769329.8
申请日：2003-09-26
申请人： Ruprecht-Karls-Universität Heidelberg , Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
发明人： SUTTER, Gerd , BUJARD, Hermann , WESTERFELD, Nicole , MIAO, Jun
IPC分类号： C12N15/30 , C12N15/863 , A61K39/002
CPC分类号： C12N15/86 , A61K39/015 , A61K2039/5256 , C12N2710/24143 , Y02A50/412
摘要： The invention relates to MVA-based recombinant viruses comprising at least one nucleic acid coding for Plasmodium falciparum MSP-1 protein, a fragment or mutein thereof. The invention also relates to a method for the production of recombinant viruses, virus-containing vaccines and to the utilization of said recombinant viruses for the prophylaxis and/or therapy of malaria.

9. 发明授权

EP1664097B1 PIROPLASMID VACCINE 有权
标题翻译： PIROPLASMID疫苗
公开(公告)号：EP1664097B1
公开(公告)日：2009-11-11
申请号：EP04787138.9
申请日：2004-09-14
申请人： Universiteit Utrecht Holding B.V.
发明人： DE VRIES, Erik , GAFFAR, Fasilla, Razzia , YATSUDA, Ana, Patricia , SCHAAP, Theodorus, Cornelis
IPC分类号： C07K14/44 , A61K39/018 , C12N15/30 , C07K16/20
CPC分类号： C07K14/44
摘要： The invention relates to a Piroplasmid protein or an immunogenic fragment of said protein, and to a nucleic acid encoding said Piroplasmid protein or said immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising said nucleic acid. Also the invention relates to host cells comprising said cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of said protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.

10. 发明授权

EP1567189B1 MALARIA VACCINE 有权
标题翻译：疟疾VAKZINE
公开(公告)号：EP1567189B1
公开(公告)日：2009-05-27
申请号：EP03810941.9
申请日：2003-11-06
申请人： Statens Serum Institut
发明人： THEISEN, Michael , JEPSEN, Søren
IPC分类号： A61K39/015 , C12N15/30 , A61P33/06 , C07K14/445
CPC分类号： C07K14/445 , A61K39/015 , C07K2319/00 , Y02A50/412
摘要： The vaccine comprises chimeric malaria proteins derived from Plasmodium falciparum genetically coupled to Plasmodium falcinarum Merozoite surface protein 3. The vaccine is produced in Lactococcus lactis as a secreted recombinant hybrid protein. Experiments show that the Glutamate-rich protein part of the hybrid increases the overall antibody response. - Immunizations with the hybrid protein consistently generates a stronger antibody response against the individual Glutamate rich protein and Merozoite surface protein 3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites.
摘要翻译：该疫苗包含衍生自恶性疟原虫的遗传偶联镰孢裂殖酵母表面蛋白3的嵌合疟疾蛋白。疫苗在乳酸乳球菌中作为分泌型重组杂交蛋白产生。实验表明，杂交的富含谷氨酸的蛋白质部分增加了总体抗体应答。 - 与两个不同位点同时注射的两个重组分子注射的两个重组分子的混合物相比，混合蛋白的免疫一贯地产生比单独的富含谷氨酸盐蛋白质和裂殖子表面蛋白3结构域更强的抗体应答。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式